A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer.
about
Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancerOptimal management of the elderly patient with head and neck cancer: Issues regarding surgery, irradiation and chemotherapyThe efficacy of an induction chemotherapy combination with docetaxel, cisplatin, and 5-FU followed by concurrent chemoradiotherapy in advanced head and neck cancer.The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.Effects of comorbidities and functional living activities on survival in geriatric breast cancer patients.Geriatric assessment in older patients with breast cancer.Treatment options for early breast cancer in elderly women.The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation.Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center.Treatment of elderly cancer patients with chemotherapy.Clinical pharmacology of cancer therapies in older adults.Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer.Pharmacokinetic dosage guidelines for elderly subjects.Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.Pharmacokinetics of chemotherapy in the older patient.Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancerClinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer.Effect of age on drug metabolism in women with breast cancer.Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer.Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.Therapeutic management of breast cancer in the elderly.Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer.An update on adjuvant systemic therapy for elderly patients with early breast cancer.Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score.Time trends in the outcome of elderly patients with breast cancer.Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics.Quality of life of elderly patients with solid tumours undergoing adjuvant cancer therapy: a systematic review.Predicting 90-Day Mortality in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma after Curative Surgery
P2860
Q26864932-ED086DD1-EF41-4CC5-8353-213402EA09A4Q28083540-B3AFE36E-2EB6-4D45-9570-097AE7BE25D1Q33386187-3773B507-C095-417B-AAD3-384A7B06E41DQ34095827-47CFE4AF-9287-4BBD-B60F-DFE4391561CAQ34721587-B7233161-AA8A-4301-B424-3288690E6AE7Q35428376-80B88058-35F7-4408-B35E-34CD50C24208Q35728668-95E9FBEC-E1E5-4296-95A4-F794AC59C2ACQ35867279-A36E79C1-4CAF-4DB8-87BC-695519180681Q36261369-EE7B1478-5578-4EBB-AB98-56DFFA9C4536Q36276360-46FF3293-076E-4700-B7D8-53F32F6C0D7DQ36459787-56DAE1CC-1D58-4756-BEBC-003B455F5A3BQ36506987-FC630D97-812A-49A0-B3CA-5713354AC8CDQ36572624-847F6BE8-CDFB-4FA0-8715-66AE49F16EACQ36610747-66F19623-C55E-4531-9015-8042A22AF1D3Q36715263-43FDE3B9-2E4B-42B6-9DE2-DC027ED2F06DQ36760924-8A425E31-4857-4295-9010-574D21BDC200Q36814437-B2EBCCA2-F769-477A-A97F-01C1C7402F3CQ37038642-F0E212C5-8299-462F-9BAD-823200DB5457Q37262883-DC78597D-DF6F-4E13-B2C2-F7C69BD44BC3Q37325560-DDCC18DF-C807-4C9F-9A1D-A14235319673Q37659124-E8CBEC80-A7C0-4577-B693-B3B9C9132F68Q37801220-7A3269E9-E4EF-44A6-8265-DE4ECBB1AE1FQ37842506-C9E47155-6E3D-41B5-A047-AA03D415DA24Q38636006-E75F94C1-13A9-4E0C-A047-FDF8B46A2E6BQ38931502-17F23737-D47B-4056-AA1A-CA8A682FEB9AQ39688507-D375E088-AAEB-467A-AF36-A2D3D0C75770Q40118030-8F4E1BF5-D4E6-4E38-8BBE-F5E72A100CB7Q40806854-C7A22576-2C46-4222-8D6F-44116B15994CQ45117158-191474B2-C0C6-4255-8C79-3FB019312397Q49444970-7C42AF23-E7DC-45E2-BA45-82ACD9E9B9D1Q58579220-52EF155D-4E14-4998-B1C6-A79C929E89D9
P2860
A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
A prospective pharmacologic ev ...... y in women with breast cancer.
@en
A prospective pharmacologic ev ...... y in women with breast cancer.
@nl
type
label
A prospective pharmacologic ev ...... y in women with breast cancer.
@en
A prospective pharmacologic ev ...... y in women with breast cancer.
@nl
prefLabel
A prospective pharmacologic ev ...... y in women with breast cancer.
@en
A prospective pharmacologic ev ...... y in women with breast cancer.
@nl
P2093
P2860
P1433
P1476
A prospective pharmacologic ev ...... y in women with breast cancer.
@en
P2093
Donehower RC
Fetting JH
Goodman SN
Grochow LB
O'Reilly S
Sartorius S
P2860
P304
P356
10.3109/07357900009012191
P577
2000-01-01T00:00:00Z